Study results, reported at the meeting and recently published (Front. Oncol. 2012;2:181), showed that 3 months after treatment, 50% of patients had a complete response, 46% had a partial response, and 4% had stable disease, according to Dr. Kunos.
At 6 months, the rate of clinical benefit – capturing patients with a complete response, partial response, or stable disease – was 68%.
Ultimately, 62% of patients had progression in a nontargeted disease site, and 40% died from disease progression.
"Reversible fatigue lasting up to 1 week after treatment was the most noticeable toxicity," Dr. Kunos said. In the first 30 days after treatment, the most common adverse effects were grade 2 fatigue, seen in 16% of patients, and grade 2 nausea, seen in 8%. Only 2% of patients had grade 3 diarrhea, and only 2% had grade 4 hyperbilirubinemia.
Dr. Kunos disclosed that he had no relevant conflicts of interest.